TY - JOUR
T1 - TRK fusion positive cancers
T2 - From first clinical data of a TRK inhibitor to future directions
AU - Roviello, Giandomenico
AU - D'Angelo, Alberto
AU - Sciortino, Marianna
AU - Mini, Enrico
AU - Nobili, Stefania
AU - De Logu, Francesco
AU - Massi, Daniela
N1 - Copyright © 2020 Elsevier B.V. All rights reserved.
PY - 2020/8/31
Y1 - 2020/8/31
N2 - Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK inhibitor, has shown remarkable efficacy in a novel "basket" study which has enrolled patients from infants to elderly with different TRK fusion-positive cancers. In this review, we focus on the challenges and expectations on the development of "tumour-agnostic" targeted therapies in rare malignancies.
AB - Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK inhibitor, has shown remarkable efficacy in a novel "basket" study which has enrolled patients from infants to elderly with different TRK fusion-positive cancers. In this review, we focus on the challenges and expectations on the development of "tumour-agnostic" targeted therapies in rare malignancies.
U2 - 10.1016/j.critrevonc.2020.103011
DO - 10.1016/j.critrevonc.2020.103011
M3 - Review article
C2 - 32521311
SN - 1040-8428
VL - 152
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103011
ER -
